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1. Random Mutagenesis of Prokaryotic Lectins
RPL-Gal1 is derived from a bacterial lectin with a specificity for terminal
α-linked galactose. It was cloned into an E. coli expression vector with
purification tags at either the N- or C-terminus, then expressed and
purified.
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2. High-Throughput RPL Mutant Expression & Screening
3. Functional Evaluation of RPL Mutants
Figure 2: ELLA analysis of selected mutants from clone library
demonstrating altered carbohydrate specificity. The RPL mutants
were screened against a panel of glycoproteins displaying a range of
glycan structures.
Random mutagenesis within the nucleotide sequence encoding the
RPL-Gal1 carbohydrate binding site was performed, resulting in
approximately 1000 Escherichia coli KRX transformants. High-
throughput protein expression of selected RPL-Gal1 mutants was
performed through a 96-deepwell format array with an E. coli strain
harbouring mutant clones. In-situ chemical lysis facilitated screening
of the entire array through ELLA.
Figure 5: Association constants of the lectins on the Lactosamine-BSA
neoglycoconjugate were determined by ELLA. Binding affinities on this
substrate range from 55 ng/mL (RPL-Gal1 ME6) to 2.8 mg/mL (RPL-
Gal1).
Neoglycoproteins, BSA conjugated to Gal-α-1,3-Gal or Gal-b-1,4-
GlcNAc, were used to determine the specificity and affinity of the most
active mutants. Affinity analysis was performed through lectin dilution
ELLA and through competitive carbohydrate inhibition ELLA.
Figure 4: Investigation of RPL-Gal mutants by ELLA using
neoglycoproteins. The parent lectin, RPL-Gal1, is specific for terminal
a-linked galactose, but the mutants show a capacity to interact with a-
or b-linked galactose (RPL-Gal1 MB10, RPL-Gal1 MB4) or display a
switch in specificity for b-linked galactose (. RPL-Gal1 MC5, RPL-Gal1
MF6).
Aims:
 Generation of a library of recombinant prokaryotic lectins (RPL’s) through random
mutagenesis of the carbohydrate binding sites of bacterial lectins.
 Characterisation of mutant lectins with respect to structure and specificity
 Provision of mutant RPL’s with enhanced affinity and/or altered specificity,
alongside wild-type RPL’s, for glycoprotein analysis and purification in WP 2.1 and
WP 2.2.
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Figure 2: RPL-Gal1 monomer with a single
bound galactose molecule (green). Galactose
binds directly to a calcium ion in the binding site
(yellow). Calcium binding amino acids are
coloured red. Mutagenesis experiments were
designed to alter the residues coloured blue.
Figure 1: (A)
Haemagglutination assay
comparing RPL-Gal1 tagged at
the N- (RPL-Gal1N) or C-
terminus (RPL-Gal1C). RPL-
Gal1C is the most active of the
two lectins. However, only
RPL-Gal1N is detectable in an
Enzyme Linked Lectin Assay
(ELLA) (B).
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Since a high throughput assay is required for screening RPL-Gal1
mutants, further studies were performed using RPL-Gal1N.
4. Project outputs
 This work is encompassed in a patent application which is in
preparation.
 Publication will be withheld pending patent submission.
 An Enterprise Ireland Commercialisation grant has been awarded to
Dr Paul Clarke to commercialise this research: CF 2011 1052
“ProLegere – Glycoseparation Solutions for the Life Science
Industries”
